BPC-157
Synthetic peptide studied for accelerated tissue repair, gut protection, and tendon healing in preclinical models. Originally derived from a protein found in gastric juice. One of the most widely researched peptides in the US market.
What Research Shows
Studied in animal models for gastric ulcer cytoprotection, tendon and ligament repair, angiogenesis, and systemic cytoprotection via the nitric oxide system and VEGF upregulation. Studies measure collagen organisation, peak tensile strength, and mucosal blood flow. Preclinical evidence consistently shows accelerated healing across multiple tissue types; no completed human clinical trials exist.
Pros & Cons
- +Extensive preclinical evidence across multiple tissue types and injury models
- +Effective at very low doses — GI protection demonstrated at nanogram-per-kilogram levels in rodents
- +Excellent safety profile: no dose-limiting toxicity found in published animal studies up to 10 mg/kg
- +Both oral and injectable routes studied for BPC-157 (oral route active in animal GI models)
- +Complementary mechanisms: BPC-157 (NO/VEGF) + TB-500 (actin/cell migration) provide broader coverage when stacked
- +Well-characterised: among the most extensively researched peptides in preclinical literature
- −No completed human clinical trials for either compound — all evidence is from animal models
- −Injection required for most systemic applications; oral bioavailability in humans not established
- −Purity and dosing accuracy vary between Canadian vendors — COA verification is essential
- −Multi-week courses add up in cost (€25–€80 per peptide per course)
- −No regulatory approval anywhere; long-term human safety data does not exist
- −Results from animal studies may not translate to human biology
Effects Timeline
Based on published study timelines. Human extrapolation is approximate — individual results vary significantly.
Gastric ulcer models show cytoprotection within 3–7 days. Tendon and muscle models show peak measurable improvement (collagen, tensile strength) at day 14. Structural tissue healing takes longer than subjective comfort improvement.
What People Research This For
Practical Questions
What storage setup is needed for reconstituted BPC-157?
A standard refrigerator at 4°C is sufficient after reconstitution with bacteriostatic water (BAC water). This gives approximately 30 days of stability. Avoid repeated freeze/thaw cycles, which degrade the peptide. Store in light-opaque vials. Lyophilised (freeze-dried) powder before reconstitution is stable at −20°C for much longer.
What should I look for on a vendor's Certificate of Analysis (COA) for BPC-157?
Look for: HPLC purity ≥98%, mass spectrometry identity confirmation matching the correct molecular weight (1419.5 Da for BPC-157), and endotoxin testing result ≤1 EU/mg. Polar Peptides and Particle Peptides publish COAs directly on their product pages. Avoid vendors who cannot produce these documents on request.
What are the most common reconstitution errors?
The most frequent errors are: using plain distilled or tap water instead of bacteriostatic water (causes bacterial contamination risk), injecting water directly onto the peptide powder forcefully (causes foaming that can denature the peptide — always drip water down the vial side), and storing reconstituted peptide at room temperature. Swirl gently to mix; never shake.
What is the typical dosing range used in studies, and how long do courses run?
Animal studies use BPC-157 at 10 ng/kg to 10 µg/kg once or twice daily, for 7–21 days depending on the injury model. TB-500 is typically 2.5 mg per animal (rat) once or twice weekly. Self-researchers commonly report using 4–12 week courses. There is no established safe or effective human dose — these figures are extrapolated from preclinical data only.
Where to Buy BPC-157 in Canada
4 Canada-accessible vendors currently stock BPC-157, including 2 with domestic warehouse. Compare prices and availability below.